Investor Presentaiton
R&D investor presentation
NASH is a progressive disease with no existing treatment and low
diagnosis rates
The prevalence of NASH is high, yet the number of
treated patients is low
Milestones for NASH in 2020 and 2021
2018
2019
2020
2021
53%
19 million
patients
NASH
Phase 2b Semaglutide NASH
Phase 2b
10%
4 million
patients
Phase 1
37%
14 million
patients
From 2020 to 2030 the number of
treated patients is expected to increase
from 0.1 million to 1.5 million
Phase 2a
F4-Sema
MRI-Sema
Gilead: Sema
combo
FXR and ACC
16
NASH patients numbers are based on internal estimates. Prevalence numbers include
patients with liver fibrosis stages 0, 1, 2, 3, and 4. Treated patients includes patients with
liver fibrosis stages 2, 3, and 4
Gilead: Sema combo: semaglutide in loose combination with firsocostat (ACC) or
cilofexor (FXR) for the treatment of NASH. ACC: acetyl-CoA carboxylase; FXR:
farnesoid X receptor; MRI: magnetic resonance imaging; NASH: non-alcoholic
steatohepatitis.
novo nordiskView entire presentation